Sermorelin
ProtocolScheduling Sermorelin alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. The 29-amino-acid biologically active fragment of GHRH — once FDA-approved for pediatric GH deficiency, now widely used off-label for adult age-related GH decline. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.
Key Takeaways
Scheduling lens: Sermorelin's ~10-20 min half-life via subq places it in the multi-daily-dosing bucket. Mechanism: GHRH receptor agonist on pituitary somatotrophs. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
GHRH receptor agonist on pituitary somatotrophs. Stimulates endogenous GH release while preserving the natural pulsatile pattern and negative feedback regulation, which lowers the risk of receptor desensitisation compared to exogenous GH. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Sermorelin.
Cycle length and off-cycle planning
Standard Sermorelin cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Sermorelin protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Sermorelin schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
Sermorelin with a ~10-20 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily SubQ (evening), with consistency mattering more than the absolute clock time of any single dose.
For off-time scheduling, Sermorelin is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for Sermorelin in cycle design starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for Sermorelin in travel considerations is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For maintenance phase scheduling, Sermorelin is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 200-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 120-500 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 200-500 mcg | 1x daily SubQ (evening) |
| Maintenance phase | SubQ | 140-500 mcg | Ongoing with periodic pauses |
Dose timing for Sermorelin is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.
Sermorelin stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Sermorelin + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Sermorelin's mechanism in protocol / scheduling / cycling protocols.
- Sermorelin + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Sermorelin's mechanism in protocol / scheduling / cycling protocols.
- Sermorelin + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Sermorelin's mechanism in protocol / scheduling / cycling protocols.
- Sermorelin + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Sermorelin's mechanism in protocol / scheduling / cycling protocols.
Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH.
Lens-specific safety considerations for protocol / scheduling / cycling use of Sermorelin: Site reactions occasional. Headache, flushing possible. Long pulsatile use generally safer than exogenous GH. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Sermorelin | Truncated GHRH analogue | ~10-20 min | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Daily timing for Sermorelin?
Cycle length and off-cycle period?
Can I shift my schedule with travel?
When to integrate Sermorelin into an existing stack?
What is Sermorelin?
What does Sermorelin stack well with?
Start a Sermorelin Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Sermorelin and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 3358 Da
- Sequence length
- 29 aa
- Half-life
- ~10-20 min
- WADA
- Banned (S2)
- FDA
- Approval withdrawn 2008 (commercial reasons); compounded prescription use widespread
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Sermorelin unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Sermorelin
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised